Find a Physician | How to Contribute | Contact Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Clinical Trial NU MD13C04

Title
A Phase II Trial of Oral Pazopanib plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) without Prior Bevacizumab Exposure and (B) after Failing Prior Bevacizumab
Principal Investigator
Jeffrey Raizer
Details
  • Status: Accepting New Patients
  • Study Type: Therapeutic, Treatment
  • Protocol No:.NU MD13C04
Purpose
The goal of this clinical research study is to learn if pazopanib when given in combination with topotecan can help to control glioblastoma. The safety of this drug combination will also be studied.
Overview
This is a phase II study, which is set up to look at the safety (side effects) and effectiveness (ability for positive change) of a new drug combination (pazopanib plus topotecan). In a phase II study, the new drug combination is tested in a group of people who have the disease or condition for which the drug was developed (recurrent glioblastoma multiforme). This is an investigational study. Pazopanib is approved by the Food and Drug Administration (FDA) and commercially available for the treatment of renal cell cancer. Topotecan is FDA approved and commercially available for the treatment of lung cancer. In this study, the combination of pazopanib and topotecan is being used for research purposes only.
Eligibility
Some of the eligibility criteria include:
  • Participants must have glioblastoma multiforme (GBM) or gliosarcoma (GS).
  • Participants must have failed prior chemoradiation with temozolomide and any other therapies.
  • Participants may have had treatment for no more than 2 prior relapses (the cancer has returned after prior therapy).
Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Description of Treatment
In this study participants will take topotecan and pazopanib by mouth 1 time everyday. Participants may take the study drugs for up to 1 year. The drug will be stopped if the disease gets worse, if bad side effects occur, or if the participant is unable to follow study directions.
Contact
Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
312.695.1102
cancertrials@northwestern.edu

Find Related Clinical Trials

Browse by Disease Sites

Other Clinical Trials by Jeffrey Raizer

last updated: 23-Nov-14 01:11 AM

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.